JP7077323B2 - キナゾリン化合物並びにその調製方法、使用及び医薬組成物 - Google Patents

キナゾリン化合物並びにその調製方法、使用及び医薬組成物 Download PDF

Info

Publication number
JP7077323B2
JP7077323B2 JP2019534817A JP2019534817A JP7077323B2 JP 7077323 B2 JP7077323 B2 JP 7077323B2 JP 2019534817 A JP2019534817 A JP 2019534817A JP 2019534817 A JP2019534817 A JP 2019534817A JP 7077323 B2 JP7077323 B2 JP 7077323B2
Authority
JP
Japan
Prior art keywords
alkyl
amino
compound
alkoxy
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019534817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503321A (ja
Inventor
ヘン シュ，
シャオガン チェン，
ソンウェン リン，
ミン ジ，
チン ジン，
デユ ウー，
チュンヤン ワン，
ユアンハオ エルブイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS and PUMC
Original Assignee
Institute of Materia Medica of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62707834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7077323(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201611204309.8A external-priority patent/CN108239074B/zh
Priority claimed from CN201611211589.5A external-priority patent/CN108239075B/zh
Priority claimed from CN201611214102.9A external-priority patent/CN108239076B/zh
Application filed by Institute of Materia Medica of CAMS and PUMC filed Critical Institute of Materia Medica of CAMS and PUMC
Publication of JP2020503321A publication Critical patent/JP2020503321A/ja
Priority to JP2022081736A priority Critical patent/JP7384535B2/ja
Priority to JP2022081738A priority patent/JP7384536B2/ja
Application granted granted Critical
Publication of JP7077323B2 publication Critical patent/JP7077323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019534817A 2016-12-26 2017-12-26 キナゾリン化合物並びにその調製方法、使用及び医薬組成物 Active JP7077323B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022081736A JP7384535B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2022081738A JP7384536B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201611204309.8A CN108239074B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611214102.9 2016-12-26
CN201611211589.5A CN108239075B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
CN201611204309.8 2016-12-26
CN201611211589.5 2016-12-26
CN201611214102.9A CN108239076B (zh) 2016-12-26 2016-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物
PCT/CN2017/118771 WO2018121550A1 (zh) 2016-12-26 2017-12-26 喹唑啉类化合物及其制备方法、用途和药物组合物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022081736A Division JP7384535B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2022081738A Division JP7384536B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物

Publications (2)

Publication Number Publication Date
JP2020503321A JP2020503321A (ja) 2020-01-30
JP7077323B2 true JP7077323B2 (ja) 2022-05-30

Family

ID=62707834

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019534817A Active JP7077323B2 (ja) 2016-12-26 2017-12-26 キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2022081738A Active JP7384536B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2022081736A Active JP7384535B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022081738A Active JP7384536B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2022081736A Active JP7384535B2 (ja) 2016-12-26 2022-05-18 キナゾリン化合物並びにその調製方法、使用及び医薬組成物

Country Status (7)

Country Link
US (3) US11534443B2 (https=)
EP (3) EP4169917B1 (https=)
JP (3) JP7077323B2 (https=)
CN (1) CN110382490A (https=)
AU (3) AU2017389818B2 (https=)
CA (3) CA3174865A1 (https=)
WO (1) WO2018121550A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534443B2 (en) * 2016-12-26 2022-12-27 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
WO2021088787A1 (zh) * 2019-11-07 2021-05-14 南京正大天晴制药有限公司 作为axl抑制剂的喹唑啉类化合物
CN113620976B (zh) * 2020-05-09 2023-09-26 中国医学科学院药物研究所 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
KR20240113496A (ko) 2021-12-03 2024-07-22 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물
CN119630431A (zh) * 2022-08-26 2025-03-14 卫材R&D管理有限公司 抗体药物缀合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
JP2010528027A (ja) 2007-05-18 2010-08-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノリン誘導体
JP2010532320A (ja) 2007-06-14 2010-10-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのキナゾリン誘導体
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008781B1 (ko) * 1993-08-05 1996-07-03 김하운 연소효율 증강장치
ES2788383T3 (es) 2000-04-25 2020-10-21 Icos Corp Inhibidores de delta fosfatidilo-inositol 3-quinasa humana
EP2984088B1 (en) * 2013-04-12 2019-03-20 Asana BioSciences, LLC Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
US11534443B2 (en) * 2016-12-26 2022-12-27 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
CN108239074B (zh) 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239075B (zh) 2016-12-26 2021-07-02 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物
CN108239076B (zh) 2016-12-26 2021-07-06 中国医学科学院药物研究所 喹唑啉类化合物及其制备方法、用途和药物组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526823A (ja) 2007-05-10 2010-08-05 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
JP2010528027A (ja) 2007-05-18 2010-08-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノリン誘導体
JP2010532320A (ja) 2007-06-14 2010-10-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのキナゾリン誘導体
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体

Also Published As

Publication number Publication date
CA3048546A1 (en) 2018-07-05
JP7384536B2 (ja) 2023-11-21
JP2022119852A (ja) 2022-08-17
EP4169918B1 (en) 2025-07-30
EP4169917B1 (en) 2025-07-30
AU2022202885A1 (en) 2022-05-26
EP4169917A1 (en) 2023-04-26
US12508263B2 (en) 2025-12-30
EP4169918B8 (en) 2025-09-24
EP4169918A1 (en) 2023-04-26
AU2022202886B2 (en) 2023-04-13
US20230113478A1 (en) 2023-04-13
AU2017389818A1 (en) 2019-08-08
US11534443B2 (en) 2022-12-27
CA3174865A1 (en) 2018-07-05
AU2022202886A1 (en) 2022-05-26
CA3174890A1 (en) 2018-07-05
JP2020503321A (ja) 2020-01-30
US20230110550A1 (en) 2023-04-13
WO2018121550A1 (zh) 2018-07-05
EP3560921A4 (en) 2020-07-29
JP2022119853A (ja) 2022-08-17
AU2022202885B2 (en) 2022-10-13
CN110382490A (zh) 2019-10-25
JP7384535B2 (ja) 2023-11-21
EP3560921B1 (en) 2024-08-14
AU2017389818B2 (en) 2022-04-07
US12508264B2 (en) 2025-12-30
EP3560921A1 (en) 2019-10-30
US20210128559A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7834804B2 (ja) Ｔａｍ阻害剤としてのピロロトリアジン化合物
JP7077323B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
KR102007056B1 (ko) 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸
TWI594997B (zh) 流感病毒複製之抑制劑
EP3500569B1 (en) 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
CN110072865B (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
KR20090091350A (ko) 단백질 키나제 억제제로 유용한 ５-시아노-４-피롤로[２,３ｂ]피리딘-３-일)-피리디민 유도체
JP2024056742A (ja) キノリン誘導体から調製される新規な阻害剤
CN118974043A (zh) Polq抑制剂化合物及其应用
JP2022515309A (ja) 置換アリール化合物、その製造方法及び用途
TW202204351A (zh) 具有大環結構的化合物及其用途
CN108239075B (zh) 喹唑啉类化合物及其制备方法、用途和药物组合物
JP7168245B2 (ja) 三環式化合物
CN121127472A (zh) 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
CN108239076A (zh) 喹唑啉类化合物及其制备方法、用途和药物组合物
CN104341416A (zh) 蛋白酪氨酸激酶抑制剂及其应用
WO2022194248A1 (zh) Ctla-4小分子降解剂及其应用
CN111747927A (zh) 作为免疫调节剂的化合物及其应用
HK40057478B (zh) Hpk1抑制剂及其使用方法
CN113354630A (zh) 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用
EA048870B1 (ru) Замещенные оксоизоиндолины
BR112018069612B1 (pt) Compostos de pirrolotriazina, uso dos mesmos, composição farmacêutica que os compreende e métodos para inibir uma quinase tam, e quinase axl e mer in vitro

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220518

R150 Certificate of patent or registration of utility model

Ref document number: 7077323

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250